Navigation Links
Initiation of breast cancer treatment varies by race; patient-doctor communication is key

WASHINGTON Black women with breast cancer were found to be three times more likely than their white counterparts to delay treatment for more than 90 days a time delay associated with increased deaths from the disease, according to a new study led by researchers at Georgetown Lombardi Comprehensive Cancer Center.

But many women chose to forgo treatment altogether, and the study, published online in the May issue of Breast Cancer Research and Treatment, suggests that low satisfaction regarding communication between black women and their doctors is a significant reason why they opt out.

The study seeks a better understanding of why black women die more often after a breast cancer diagnosis than white women. Although systemic therapy has been shown to reduce mortality by up to 50 percent, researchers say black women are less likely to undergo chemotherapy after surgery a major contributing factor to the disparity in survival rates.

"When black women receive chemotherapy, their survival outcomes are similar to their white counterparts," says Vanessa B. Sheppard, PhD, an associate professor of oncology at Georgetown Lombardi.

For the study, 359 women with invasive, non-metastatic breast cancer for whom chemotherapy would be considered curative were enrolled (58 percent black; 42 percent white) from three hospitals in Washington and one in Detroit. Participants were asked about their experiences with their oncologists and other questions about marital status and religion.

Thirty-nine percent of study participants chose to receive chemotherapy after surgery, but there was significant variation in when they started treatment.

Women who reported having lower trust in their oncologists and who were single were more likely to experience a delay in treatment; the average delay was 71.8 days for black women, compared with a delay of 55 days for white women.

In addition, overall, black women who identified themselves as religious and single were three times more likely than white women (27 percent versus 8.3 percent) to delay treatment for more than 90 days.

"Unmarried women might not have the support at home and may need more time to plan for a rigorous treatment schedule," Sheppard explains. "Women of faith might delay treatment as they seek guidance through prayer or from the religious community."

Conversely, the study also showed that white women who reported more communication with their doctor were more likely to forgo treatment.

"Black women may have preferred to rely on providers while whites may have preferred to make decisions with less input from providers," the researchers suggest. They cite other studies that have found that even when black breast cancer patients asked their doctors more questions than whites, they received less information.

Sheppard suggests, "If black women in this study relied more on their physicians in making decisions than whites, when they received their desired level of communication, their decisions may have been positively impacted."

Sheppard said one reassuring finding was that, of all women who qualified for chemotherapy, those with clinical factors indicating a greater benefit from treatment were more likely to choose to receive therapy.

The researchers say additional studies can help understand communication preferences, but until that point they conclude that doctor-patient communications "offer a good leverage point for interventions to improve chemotherapy patterns in black women and ultimately, to reduce race disparities in breast cancer mortality."


Contact: Karen Mallet
Georgetown University Medical Center

Related medicine news :

1. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
2. RANK protein promotes the initiation, progression and metastasis of human breast cancer
3. Study Shows Dual Targeting of HER2 and HR-positive Metastatic Breast Cancer Improves Survival Rates
4. Exercise-related changes in estrogen metabolism may lower breast cancer risk
5. Longer Wait for Mammogram After Benign Breast Biopsy May Be Warranted
6. Gene expression test distinguishes between breast cancer patients at high and low risk of late recurrence
7. New genetic clues to breast and ovarian cancer
8. Breast augmentation patients report high satisfaction rates, says study
9. Implants May Delay Breast Cancer Detection, Raise Death Risk
10. Study Looks at Vitamin D Needs in Breast-Fed Babies
11. Decoded: Molecular messages that tell prostate and breast cancers to spread
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... for the care management and population health arenas, is pleased to announce that ... cost containment services, has successfully implemented the ACUITY Complete Care™ Management to back ...
(Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Arash Moradzadeh ... Man for 2015. , Angeleno Magazine is a division of Modern Luxury, ... 1994, Modern Luxury includes more than 50 magazine titles across 15 major markets. ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announced today that it has officially launched a sleek, mobile-ready and user-centric redesigned ... his company’s new website clearly outlines the benefits that its SEO services provide ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015 Breg, Inc ., a premier ... that it has been awarded three contracts by Novation, ... Novation will have access to improved pricing for Breg,s ... soft goods dedicated to advancing orthopedic care.  ... U.S. population, rising prevalence of chronic conditions and the ...
(Date:12/1/2015)... Russia has always been a country of choice ... in Europe in 2015 were tested in phase ... has always been a country of choice for global multi-center ... Europe in 2015 were tested in phase II-III clinical ... has always been a country of choice for global multi-center phase III ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology: